Author:
Rosdah Ayeshah A.,Abbott Belinda M.,Langendorf Christopher G.,Deng Yali,Truong Jia Q.,Waddell Helen M. M.,Ling Naomi X. Y.,Smiles William J.,Delbridge Lea M. D.,Liu Guei-Sheung,Oakhill Jonathan S.,Lim Shiang Y.,Holien Jessica K.
Abstract
AbstractMitochondrial dynamin-related protein 1 (Drp1) is a large GTPase regulator of mitochondrial dynamics and is known to play an important role in numerous pathophysiological processes. Despite being the most widely used Drp1 inhibitor, the specificity of Mdivi-1 towards human Drp1 has not been definitively proven and there have been numerous issues reported with its use including off-target effects. In our hands Mdivi-1 showed varying binding affinities toward human Drp1, potentially impacted by compound aggregation. Herein, we sought to identify a novel small molecule inhibitor of Drp1. From an initial virtual screening, we identified DRP1i27 as a compound which directly bound to the human isoform 3 of Drp1 via surface plasmon resonance and microscale thermophoresis. Importantly, DRP1i27 was found to have a dose-dependent increase in the cellular networks of fused mitochondria but had no effect in Drp1 knock-out cells. Further analogues of this compound were identified and screened, though none displayed greater affinity to human Drp1 isoform 3 than DRP1i27. To date, this is the first small molecule inhibitor shown to directly bind to human Drp1.
Funder
Australia awards scholarship
Jack Brockhoff Foundation
NHMRC Early Career Research Fellow
EH Flack fellowship
Australian Research Council
RMIT Vice Chancellors Fellowship
5point Foundation
Publisher
Springer Science and Business Media LLC
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献